# OnCo record nct03268954 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03268954/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03268954", "NCT03268954" ;
  schema:name "Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)"@en ;
  schema:description "A phase 3 trial of Azacitidine and Pevonedistat in Leukaemia, run by Takeda, completed."@en ;
  schema:url <https://onco.cc/trials/nct03268954/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03268954> ;
  onco:status "completed" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/leukaemia/> ;
  onco:drugs <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/drugs/pevonedistat/> ;
  onco:companies <https://onco.cc/companies/takeda/> .